参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Cutaneous Melanoma Version 2.2019-March 12,2019.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Eggermont AMM,Blank CU,Mandala M,et al.Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.N Engl J Med 2018, 378:1789-1801.
4.National Institutes of Health.Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery.
5.Kibbi N,Kluger H,Choi JN.Melanoma:Clinical Presentations.Cancer Treat Res 2016, 167:107-129.
6.Maio M,Lewis K,Demidov L,et al.Adjuvant vemurafenib in resected,BRAF(V600) mutation-positive melanoma (BRIM8):a randomised,doubleblind,placebocontrolled,multicentre,phase 3 trial.Lancet Oncol 2018, 19:510-520.
7.National Institutes of Health.A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma.
8.Ji AL,Bichakjian CK,Swetter SM.Molecular Profiling in Cutaneous Melanoma.J Natl Compr Canc Netw 2016, 14:475-480.
9.E.R.Squibb & Sons,LLC.Prescribing information:YERVOY® (ipilimumab) injection,for intravenous use.2018.
10.Theodore JE,Frankel AJ,Thomas JM,et al.Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma.ANZ J Surg 2017, 87:44-48.
11.Laas E,Mallon P,Duhoux FP,et al.Low concordance between gene expression Signatures in ER positive HER2 negative breast carcinoma could impair their clinical application.PLoS One 2016, 11:e0148957.
12.Array BioPharma Inc.Prescribing information:MEKTOVI (binimetinib) tablets,for oral use.2018.(https://www.daowen.com)
13.Jakub JW,Terando AM,Sarnaik A,et al.Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFEMILND):Report of a Prospective Multi-institutional Trial.Ann Surg 2017, 265:192-196.
14.Larkin J,Minor D,D'Angelo S,et al.Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037:A Randomized,Controlled,Open-Label Phase III Trial.J Clin Oncol 2018, 36:383-390.
15.Ives NJ,Suciu S,Eggermont AMM,et al.Adjuvant interferon-alpha for the treatment of high-risk melanoma:An individual patient data metaanalysis.Eur J Cancer 2017, 82:171-183.
16.Schule SC,Eigentler TK,Garbe C,et al.Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.Eur J Nucl Med Mol Imaging 2016, 43:482-488.
17.Amaria RN,Prieto PA,Tetzlaff MT,et al.Neoadjuvant plus adjuvant daBRAFenib and trametinib versus standard of care in patients with highrisk,surgically resectable melanoma:a single-centre,open-label,randomised,phase 2 trial.Lancet Oncol 2018, 19:181-193.
18.Gershenwald JE,Scolyer RA,Hess KR,et al.Melanoma staging:Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J Clin 2017, 67:472-492.
19.Minniti G,Scaringi C,Paolini S,et al.Repeated stereotactic radiosurgery for patients with progressive brain metastases.J Neurooncol 2016, 126:91-97.
20.Blank CU,Rozeman EA,Fanchi LF,et al.Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.Nat Med 2018.
21.Faries MB,Thompson JF,Cochran AJ,et al.Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.N Engl J Med 2017, 376:2211-2222.
22.Wat H,Senthilselvan A,Salopek TG.A retrospective,multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.J Am Acad Dermatol 2016, 74:94-101.
23.National Institutes of Health.Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery.